A modeling study published in PLOS Medicine on February 20, 2026, warns of a staggering economic fallout from recent and projected cuts to U.S. foreign aid. Researchers from Boston University, the London School of Hygiene & Tropical Medicine, and Harvard University estimate that the termination of USAID support for tuberculosis (TB) programs will impose an additional $7.5 billion in costs on households in low- and middle-income countries (LMICs) by 2050.
The study highlights a grim reality for global health equity, noting that nearly 4 million additional households are projected to face “catastrophic costs”—expenditures exceeding 20% of their annual income—directly due to the loss of bilateral U.S. funding.
The Economic “Worst-Case” Scenario
While the $7.5 billion figure accounts for USAID termination alone, the researchers modeled more severe scenarios involving broader international funding collapses.
- Scenario A (USAID Only): $7.5 billion in added patient costs; 3.9 million more households face catastrophic expenses.
- Scenario B (USAID + US Global Fund Cuts): Costs jump to $24 billion if the U.S. also withdraws from the Global Fund to Fight AIDS, TB, and Malaria.
- Scenario C (Total International Withdrawal): In the absolute worst-case, the economic burden reaches $79.7 billion, with over 40 million households pushed into financial ruin.
Disproportionate Impact on the Poorest
The study utilized data from 79 LMICs, representing 91% of global TB cases, to map the burden across income levels.
| Income Quintile | Share of Catastrophic Costs | Impact Description |
| Poorest 20% | >50% | The most vulnerable face the highest risk of “medical impoverishment.” |
| Middle 40% | ~35% | Significant risk of debt-traps and asset depletion. |
| Wealthiest 40% | <15% | Better able to absorb direct costs, though still impacted by service loss. |
The Mechanism of “Catastrophic Cost”
When international aid for diagnostics and treatment vanishes, the financial burden shifts directly to the patient in three major ways:
- Direct Medical Costs: Paying for specialized TB drugs and laboratory tests that were previously subsidized.
- Non-Medical Costs: Travel to distant clinics and specialized nutritional support required for recovery.
- Indirect Costs (Income Loss): TB often prevents patients from working for months; without aid-funded “rapid-recovery” protocols, this lost income becomes a permanent economic setback.
[Image: A bar chart showing the projected increase in catastrophic costs by income quintile, with the largest bar representing the poorest 20% of the population.]
Key Takeaways
- Reversing Decades of Progress: USAID has historically funded nearly 20% of global TB services, helping prevent an estimated 75 million deaths since its inception.
- A “De Facto” Dissolution: The study comes amid the “dismantling” of USAID following an 83% budget cut announced by the second Trump administration in early 2025.
- The Domestic Pivot: Lead author Dr. Allison Portnoy stresses that LMICs must now urgently strengthen domestic financing and integrate TB services into primary healthcare to survive the “funding cliff.”
Sources
- PLOS Medicine: The potential impact of reduced international donor funding on the household economic burden of tuberculosis, Feb 20, 2026.
- Boston University SPH: Foreign Aid Cuts to TB Services Could Cost Families $80 Billion Worldwide, March 11, 2026.
- Press Trust of India (PTI): Cuts to USAID could generate USD 7.5 bn additional costs, March 13, 2026.
Leave a Reply